Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457469 | 0.78 | ABL1 (0.30) | — | |
| SCHEMBL20882141 | 0.69 | KDM4E (0.35) | KDM4EALDH1A1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL458421 | 0.67 | TTK (0.36) | — | |
| SCHEMBL458023 | 0.66 | IKBKB (0.32) | KDM4EALDH1A1POLB | |
| SCHEMBL23782086 | 0.65 | HTR6 (0.32) | — | |
| SCHEMBL19336865 | 0.63 | KDM4E (0.43) | KDM4EPOLB | |
| SCHEMBL456244 | 0.63 | TTK (0.33) | — | |
| SCHEMBL455367 | 0.59 | ABL1 (0.32) | — | |
| SCHEMBL31244494 | 0.58 | — | — | |
| SCHEMBL627244 | 0.58 | CDK2 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961752-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2961752-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9512130-B2 | Substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512130-B2 | Substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512130-B2 | Substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| EP-3007698-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-9255100-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| US-20160016959-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2614063-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2614063-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2961752-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014198776-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014131739-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014131739-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014020041-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-06 | — | — | WO | disclosed |
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BUB1, BUB1B, CDK1 | KDM4E 2860/4885ALDH1A1 3808/4885POLB 2574/4885 |
| US-20160016959-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | VEGFA, PGF, VHL | KDM4E 1795/4885ALDH1A1 776/4885POLB 909/4885 |
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BUB1, TTBK1, BUB1B | KDM4E 3968/4885ALDH1A1 3389/4885POLB 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.